WO2021193553A1 - 多量体IgA抗体の作製法及び多重特異性多量体IgA抗体 - Google Patents
多量体IgA抗体の作製法及び多重特異性多量体IgA抗体 Download PDFInfo
- Publication number
- WO2021193553A1 WO2021193553A1 PCT/JP2021/011753 JP2021011753W WO2021193553A1 WO 2021193553 A1 WO2021193553 A1 WO 2021193553A1 JP 2021011753 W JP2021011753 W JP 2021011753W WO 2021193553 A1 WO2021193553 A1 WO 2021193553A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- iga antibody
- iga
- binding site
- antigen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000002156 mixing Methods 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 36
- 239000000427 antigen Substances 0.000 claims description 79
- 102000036639 antigens Human genes 0.000 claims description 79
- 108091007433 antigens Proteins 0.000 claims description 79
- 230000027455 binding Effects 0.000 claims description 69
- 239000000539 dimer Substances 0.000 claims description 57
- 239000013638 trimer Substances 0.000 claims description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 14
- 108090000769 Isomerases Proteins 0.000 claims description 14
- 102000004195 Isomerases Human genes 0.000 claims description 14
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 13
- 230000003248 secreting effect Effects 0.000 claims description 13
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 108010024636 Glutathione Proteins 0.000 claims description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 9
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 8
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 8
- 210000004748 cultured cell Anatomy 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 102400001107 Secretory component Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 37
- 150000001413 amino acids Chemical group 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 108091008146 restriction endonucleases Proteins 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 101710154606 Hemagglutinin Proteins 0.000 description 16
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 16
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 16
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 15
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 15
- 101710176177 Protein A56 Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 230000004927 fusion Effects 0.000 description 14
- 239000000185 hemagglutinin Substances 0.000 description 14
- 239000000178 monomer Substances 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 101150095279 PIGR gene Proteins 0.000 description 7
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010059013 Chaperonin 10 Proteins 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100023737 GrpE protein homolog 1, mitochondrial Human genes 0.000 description 2
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 2
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000829489 Homo sapiens GrpE protein homolog 1, mitochondrial Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- -1 GroE Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710131079 Polymeric immunoglobulin receptor Proteins 0.000 description 1
- 102100035187 Polymeric immunoglobulin receptor Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241001535172 Severe fever with thrombocytopenia virus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003287 lymphocyte surface marker Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
Definitions
- the present invention relates to a method for producing a multispecific IgA antibody, preferably a multispecific multimeric IgA antibody, and a multispecific multimeric IgA antibody.
- IgA antibody which is the most produced antibody in the body, functions as a front-line defense factor for the body's defense against respiratory infections targeting mucosal tissues such as influenza.
- This secretory IgA antibody forms a multimer of a dimer or more, and it has been clarified that the tetramer SIgA has higher functional activity than IgG or monomeric IgA.
- Multispecific antibodies in which different variable regions are mounted on a plurality of Fabs existing in the antibody have been put into practical use.
- Multispecific antibodies are technologies that are expected to be applied not only in antibody drugs but also in various fields such as the development of research tools and diagnostic agents.
- the production method is complicated, and a great deal of labor is required to produce one multispecific antibody, so that the types of multispecific antibodies that have been put into practical use are limited.
- An object of the present invention is to provide a method for easily and efficiently producing a multimeric IgA antibody, particularly a multispecific multispecific IgA antibody.
- the present inventors mixed a dimeric IgA antibody, a monomeric IgA antibody, and a secretory component (hereinafter, also referred to as “SC”) prepared in separate cultured cells in vitro.
- SC secretory component
- bispecific trimer and tetramer IgA antibodies can be produced easily and efficiently, and the present invention has been completed.
- bispecific trimer and tetramer IgA antibodies can be produced in the same manner when the secretory components are not mixed, although the efficiency is lower than when they are mixed.
- the techniques of the present invention include not only bispecific trimers and tetramers, but also monospecific trimers and tetramers, and trispecific or higher multispecific trimers and tetramers. It can also be applied to the production of body antibodies.
- the present invention comprises [1] a method for producing a trimer and a tetramer IgA antibody, which comprises mixing a dimeric IgA antibody and a monomeric IgA antibody. [2] The method according to [1], which comprises further mixing secretory components. [3] At least bispecific trimeric and tetrameric IgA antibodies, wherein the dimeric IgA antibody comprises a first antigen binding site and the monomeric IgA antibody comprises a second antigen binding site. The method according to [1] or [2], wherein [4] The method according to [3], wherein another monomeric IgA antibody containing a third antigen binding site is further mixed.
- the four Fab regions of the dimer IgA antibody each contain a first antigen-binding site, and the two Fab regions of a monomeric IgA antibody containing the second antigen-binding site each contain a second antigen.
- the four Fab regions of the dimer IgA antibody each contain a first antigen-binding site, and the two Fab regions of a monomeric IgA antibody containing the second antigen-binding site each contain a second antigen.
- the method according to [4], wherein the two Fab regions of the other monomeric IgA antibody contain a binding site, each containing a third antigen binding site.
- antibody [15] A polymer of one molecule of a dimeric IgA antibody containing a first antigen-binding site, one or two molecules of a monomeric IgA antibody containing a second antigen-binding site, and a secretory component.
- the multimeric IgA antibody of the present invention carries four Fab regions derived from one dimeric IgA antibody and two or four Fab regions derived from a monomeric IgA antibody in one antibody molecule. Thereby, it is possible to have one kind or two or more kinds of Fab regions. Therefore, according to the present invention, a multimeric IgA antibody, particularly a multispecific multimeric IgA antibody, can be obtained.
- the multimeric IgA antibody and the multispecific multispecific IgA antibody of the present invention have high antigen-binding or neutralizing activity for each antigen.
- the dimer IgA antibody and the monomeric IgA antibody cannot be polymerized with each other in the method of the present invention, the dimer IgA antibody containing the first antigen binding site and the second antigen binding site
- the trimer and tetramer IgA antibodies produced by the method of the present invention have a 100% probability of becoming multispecific antibodies.
- the present invention comprises a simple method of simply mixing at least two proteins, a dimeric IgA antibody and a monomeric IgA antibody, in-vitro to a multimeric antibody, particularly a multispecific multimeric antibody, particularly a multispecific.
- FIG. 1 It is a schematic diagram which shows an example of the production of the bispecific tetramer IgA antibody of this application.
- the amino acid sequence of wild-type SC and the amino acid sequence of SC12-deficient mutant are shown.
- the base sequence of wild-type SC is shown.
- the nucleotide sequence of the SC12 deletion mutant is shown.
- “mA1 + dA1 + SC12” shows the result of mixing the monomeric IgA1 antibody, the dimer IgA1 antibody, and the SC12.
- “MA1 + SC12” indicates the result of mixing the monomeric IgA1 antibody and SC12.
- DA1 + SC12 indicates the result of mixing the dimer IgA1 antibody and SC12.
- Tri / Tet IgA indicates a trimer and tetramer IgA1 antibody (control) produced intracellularly. It is a graph which shows the comparison of the IgA antibody tetramer formation promoting ability of SC12 and SC-wt.
- mA1 + mC-dA1 + SC12 indicates the result of mixing the monomeric IgA1 antibody, the fluorescently labeled mCherry fusion dimer IgA1 antibody, and SC12.
- “MA1 + mC-dA1 + SC-wt” shows the result of mixing the monomeric IgA1 antibody, the fluorescently labeled mCherry fusion dimer IgA1 antibody, and the wild-type SC.
- “MC-mA1 + dA1 + SC12” shows the result of mixing the fluorescently labeled mCherry fusion type monomeric IgA1 antibody, the dimer IgA1 antibody, and SC12.
- “MC-mA1 + dA1 + SC-wt” shows the result of mixing the fluorescently labeled mCherry fusion type monomeric IgA1 antibody, the dimer IgA1 antibody, and the wild type SC.
- MC-mA1 + dA1 + SC12 shows the result of mixing the fluorescently labeled mCherry fusion type monomeric IgA1 antibody, the dimer IgA1 antibody, and SC12.
- MC-mA1 + dA1 + SC12 + Simple shows the result of mixing the fluorescently labeled mCherry fusion type monomeric IgA1 antibody, the dimer IgA1 antibody, SC12, and the additive. It is a graph which shows the IgA antibody multimer formation efficiency in the presence of a wild-type SC with and without an additive (Supple).
- mA1 + mC-dA1 + SC-wt shows the result of mixing the monomeric IgA1 antibody, the fluorescently labeled mCherry fusion dimer IgA1 antibody, and the wild-type SC.
- MA1 + mC-dA1 + SC-wt + Supple shows the result of mixing the monomeric IgA1 antibody, the fluorescently labeled mCherry fusion dimer IgA1 antibody, the wild type SC, and the additive.
- MC-mA1 + dA1 + SC-wt shows the result of mixing the fluorescently labeled mCherry fusion type monomeric IgA1 antibody, the dimer IgA1 antibody, and the wild type SC.
- MC-mA1 + dA1 + SC-wt + Supple shows the result of mixing the fluorescently labeled mCherry fusion type monomeric IgA1 antibody, the dimer IgA1 antibody, the wild type SC, and the additive. It is a graph which shows the IgA multimer formation promoting effect by each additive. It is a graph which shows the multimer formation efficiency by the difference (IgA1 and IgA2m2) of the constant region of IgA antibody. It is a graph which shows the difference of the multimer formation efficiency by the length of a reaction time.
- Hetero indicates a combination of a monomer IgA2m2 (mA2) and a dimer IgA1 (dA1) having different specificities
- Homo indicates a combination of mA2 and dA1 having the same specificity
- Antibody is a protein called immunoglobulin (Ig) and has the ability to specifically bind to an antigen.
- the antibody has a basic unit consisting of a total of four polypeptide chains, two heavy chains (H chain) and two light chains (L chain) arranged in a Y shape, and has one or more basic units. Units gather to form one antibody molecule.
- the four polypeptide chains have a constant region with relatively little change in amino acid sequence (heavy chain constant region: CH1, CH2, CH3, and light chain constant region: CL), and a large change in amino acid sequence. There are variable regions (heavy chain variable region: VH, and light chain variable region: VL).
- Multimer means an antibody containing two or more of the above basic units. As will be described later, the antibodies produced by the production method of the present application are trimer and tetramer antibodies. Thus, as used herein, “multimer” means a trimer or tetramer, or a mixture of trimers and tetramers.
- the "Fab region” is a region containing an antigen-binding site, which is composed of a heavy chain VH and CH1 domain and a light chain VL and CL domain.
- Multispecificity means that an antibody can specifically bind to two or more different epitopes (antigen determinants).
- Bispecificity means that an antibody can specifically bind to two different epitopes.
- Trispecificity means that an antibody can specifically bind to three different epitopes.
- quadruple specificity, quintuple specificity, hexaspecific specificity, seven-fold specificity, and octuple specificity mean that antibodies are associated with 4, 5, 6, 7, and 8 different epitopes, respectively. It means that it can be specifically bound.
- multispecific antibodies contain two or more antigen binding sites (paratopes), each specific for a different epitope.
- the "different epitope” may be a different epitope on the same antigen, or may be an epitope on a different antigen.
- Unispecificity means that an antibody has one or more antigen binding sites that bind to the same epitope of the same antigen.
- Antigen binding site means a region on an antibody molecule that binds to an epitope.
- Antigen binding sites include heavy chain VHs and light chain VLs.
- the first, second, third, and fourth antigen binding sites are regions consisting of different amino acid sequences that bind to epitopes on different antigens or different epitopes on the same antigen. Means.
- IgA is one of the antibody (immunoglobulin) isotypes. In the present specification, it is also referred to as "IgA antibody” or "IgA type antibody”. Human IgA is classified into two subclasses, IgA1 and IgA2, depending on the difference in the constant region. IgA2 is further divided into three allotypes, IgA2m1, IgA2m2, and IgA2 (n). IgA is mainly present as monomeric IgA in serum (serotype IgA), and IgA1 is a major component.
- Multimer IgA When secreted into the mucosa, it exists as a dimer or more multimer IgA (secretory IgA or SIgA), and IgA2 occupies about half.
- Multimer IgA is obtained by polymerizing two or more molecules of IgA with a J chain (Joining chain) or a J chain and SC. Some multimers IgA contain SC and some do not.
- Dimer IgA generally refers to a molecule with a heavy chain: light chain: J chain ratio of 4: 4: 1.
- SC secretory component
- pIgR multimeric immunoglobulin receptor
- D1 is essential for binding to multimeric IgA, and in particular, a structure similar to the CDR (complementarity determining region) of the variable region of immunoglobulin present in D1 plays an important role in binding to multimeric IgA. Carry.
- PIgR is a type I transmembrane protein that belongs to the immunoglobulin superfamily and is expressed on the cell membrane on the basement membrane side of mucosal epithelial cells, and consists of an extracellular domain, a transmembrane region, and an intracytoplasmic region.
- pIgR specifically recognizes and binds to a multimer IgA molecule containing a J chain produced by plasma cells existing in the lamina intestinal, takes it into epithelial cells, and transports it to the apical side while being bound. ..
- the proteolytic enzyme of epithelial cells cleaves between the extracellular domain of pIgR and the transmembrane region, and the multimer IgA is secreted into the luminal mucosal layer in a state of being bound to the extracellular domain portion of pIgR. (Secretory IgA or SIgA).
- the extracellular domain of pIgR after cleavage corresponds to SC.
- an IgA antibody containing SC in the molecule is referred to as a "secretory IgA antibody".
- the "J chain” is a polypeptide having an N-linked sugar chain and having a molecular weight of about 15 kDa.
- the J chain is highly conserved among organisms and is essential for the multimeric IgA to interact with pIgR.
- a method for producing a trimer and tetramer IgA antibody which comprises mixing a dimer IgA antibody and a monomeric IgA antibody.
- the manufacturing method of the present application also referred to as "the manufacturing method of the present application”
- a method for producing a trimer and tetramer IgA antibody which comprises mixing a dimeric IgA antibody, a monomeric IgA antibody, and an SC.
- one dimer IgA antibody and two monomeric IgA antibodies are polymerized to produce one tetramer IgA antibody.
- one dimer IgA antibody, two monomeric IgA antibodies, and SC are polymerized to produce one tetramer IgA antibody (FIG. 1). .. Further, according to the production method of the present application, one dimer IgA antibody and one monomeric IgA antibody are polymerized to produce one trimer IgA antibody. Furthermore, according to the production method of the present application, one dimer IgA antibody, one monomeric IgA antibody, and SC are polymerized to produce one trimer IgA antibody.
- the dimeric IgA antibody and the monomeric IgA antibody to be mixed may each contain different variable regions, or may contain the same variable region. If all variable regions of the dimeric IgA antibody and the monomeric IgA antibody are the same, the resulting trimeric and tetrameric IgA antibodies are monospecific antibodies.
- the dimeric IgA antibody and the monomeric IgA antibody contain two or more different variable regions, a double to octuple, multispecific antibody is obtained. For example, double with a dimeric IgA antibody in which all four Fab regions contain a first antigen binding site and a monomeric IgA antibody in which both of the two Fab regions contain a second antigen binding site. Specific trimeric and tetrameric IgA antibodies may be obtained.
- a dimeric IgA antibody in which all four Fab regions contain a first antigen-binding site, a first monomeric IgA antibody in which both of the two Fab regions contain a second antigen-binding site, and 2 A trispecific tetramer IgA antibody may be obtained using a second monomeric IgA antibody in which both of the Fab regions contain a third antigen binding site.
- IgA antibodies and triple or tetraspecific tetrameric IgA antibodies may be obtained.
- the desired double or hexafold multispecific trimeric IgA antibody and the desired double are obtained.
- eight-fold multispecific tetramer IgA antibody can be obtained.
- a preferred embodiment of the present invention comprises mixing a dimeric IgA antibody comprising a first antigen binding site and a monomeric IgA antibody comprising a second antigen binding site, or a first antigen binding site.
- a method for producing at least bispecific trimeric and tetrameric IgA antibodies which comprises mixing a dimer IgA antibody containing, a monomeric IgA antibody containing a second antigen binding site, and an SC.
- the dimeric IgA antibodies do not polymerize with each other, and the monomeric IgA antibodies do not polymerize with each other. Therefore, when a dimer IgA antibody containing a first antigen-binding site and a monomeric IgA antibody containing a second antigen-binding site are mixed, or a dimer IgA antibody containing a first antigen-binding site When SC is mixed with a monomeric IgA antibody containing a second antigen-binding site, at least bispecific trimeric and tetrameric IgA antibodies can be obtained with a 100% probability.
- the 458th amino acid residue in the heavy chain constant region of the dimeric IgA antibody and / or the monomeric IgA antibody to be mixed is a hydrophobic amino acid.
- the hydrophobic amino acid include isoleucine, leucine, methionine, tryptophan, and glycine, and preferred examples include isoleucine.
- the heavy chain constant region of such an IgA antibody may consist of a natural sequence, or the amino acid residue at position 458 may be modified to a hydrophobic amino acid by a gene recombination technique.
- the present invention when an IgA2m2 antibody in which the 458th amino acid residue in the heavy chain constant region is isoleucine is used, only the IgA1 antibody in which the 458th amino acid residue in the heavy chain constant region is other than a hydrophobic amino acid is used.
- the formation efficiency of the multimer IgA antibody was increased as compared with the case of using (Example 5).
- the amino acid sequence of the constant region of IgA1 is shown in SEQ ID NO: 1
- the amino acid sequence of the constant region of IgA2m2 is shown in SEQ ID NO: 2.
- SC either a wild-type SC or an SC mutant may be used.
- SC mutant include an SC mutant containing at least domain D1, and for example, a mutant lacking one or more domains of SC domains D2 to D5 or a part of a region of D2 to D5.
- SC variant containing at least domains D1 and D2, a deleted variant of SC domains D4 and D5, and a variant lacking all of SC domains D3 to D5 (referred to herein as "SC12").
- SC12 a variant lacking all of SC domains D3 to D5
- SC wild-type SC
- SC12 SEQ ID NO: 4
- SC variants include, for example, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94 of the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. %, At least 95%, at least 96%, at least 97%, at least 98%, and at least 99% of polypeptides consisting of amino acid sequences having sequence identity.
- SC may or may not be used, and SC is preferably used. The use of SC improves the efficiency of trimer and / or tetramer IgA antibody formation.
- the origin of the IgA antibody used in the production method of the present application is not particularly limited, and examples thereof include human antibody, non-human mammalian antibody, rodent-derived antibody, and bird-derived antibody.
- the antigen to which the IgA antibody specifically binds is not particularly limited.
- Appropriate IgA antibodies may be selected to produce the desired trimer IgA antibody and / or tetrameric IgA antibody.
- the subclass of IgA antibody used in the production method of the present application may be either IgA1 or IgA2, or both IgA1 and IgA2 may be used.
- both IgA1 and IgA2 may be used.
- a dimeric IgA1 antibody and a monomeric IgA2 antibody may be used.
- any allotype of IgA2 may be used.
- the IgA antibody used in the production method of the present application may be a natural IgA antibody or a recombinant IgA antibody.
- the "recombinant antibody” includes an antibody obtained by modifying a natural antibody sequence and an antibody artificially produced by a gene recombination technique regardless of the presence or absence of the sequence modification.
- a recombinant IgA antibody obtained by converting a non-IgA type antibody into an IgA type may be used.
- non-IgA type antibodies include IgG antibody, IgM antibody, IgE antibody, IgD antibody, and IgY antibody.
- the origin of the non-IgA type antibody is not particularly limited, and examples thereof include human antibody, non-human mammalian antibody, rodent-derived antibody, and bird-derived antibody.
- recombinant IgA antibodies made by transplanting the variable region of an IgG antibody into the backbone framework of an IgA antibody or by transplanting only the CDR of an IgG antibody into the CDR of an IgA antibody may be used.
- the recombinant IgA antibody includes a chimeric recombinant IgA antibody that combines a variable region of an antibody derived from one animal species and a constant region of an IgA antibody derived from another animal species, and a complementarity determining region of an antibody derived from a certain animal species.
- CDRs complementarity determining region of an antibody derived from a certain animal species.
- Genetically modified technology is well known in the art.
- the "IgA antibody” means an antibody having an amino acid sequence derived from at least a part of the IgA antibody.
- the dimeric IgA antibody used in the production method of the present application preferably does not contain SC.
- the dimeric IgA antibody used in the production method of the present application contains a J chain.
- the dimeric IgA antibody and the monomeric IgA antibody to be mixed may be prepared by a method known in the art.
- the dimeric IgA antibody and the monomeric IgA antibody may be separately prepared in cultured cells.
- the dimeric IgA antibody may be prepared, for example, by co-expressing the heavy chain protein, light chain protein and J chain constituting the IgA antibody in one host cell.
- the monomeric IgA antibody may be prepared, for example, by co-expressing the heavy chain protein and the light chain protein constituting the IgA antibody in one host cell.
- host cells include mammalian cells, insect cells, bacteria, yeast and the like.
- mammalian cells include, but are not limited to, 293F cells, CHO cells and the like.
- insect cell include, but are not limited to, an Sf9 cell line, an Sf21 cell line, and the like.
- Step of co-expressing the above proteins in one host cell.
- an expression vector containing a nucleic acid encoding these proteins may be introduced into the cell.
- Expression vectors and introduction methods are well known in the art.
- a phage vector, a viral vector, a plasmid vector or the like can be used, and a vector suitable for the host is appropriately selected by a person skilled in the art.
- the cells are cultured to express the desired protein. Cell culture conditions are appropriately selected by those skilled in the art.
- molecular chapelon protein disulfide bond isomerase, oxidized glutathione, and oxidized glutathione, and At least one substance selected from the group consisting of reduced glutathione may be further mixed.
- Molecular chaperone proteins are proteins that contribute to the folding of protein molecules.
- Molecular chaperone proteins include Hsp60 family, Hsp70 family, Hsp90 family, Hsp100 family, low molecular weight Hsp family, isomerases, and cofactors thereof, and examples thereof include Dnak, DnaJ, GrpE, GroE, GroEL, and GroES. Two or more molecular chaperone proteins may be used.
- Disulfide bond isomerases are enzymes that contribute to disulfide bonds between amino acid residues. Oxidized glutathione creates the oxidative conditions necessary to form disulfide bonds. The use of at least one of these substances promotes tetramer formation of IgA antibodies.
- At least two substances selected from the group consisting of molecular chapelone protein, disulfide bond isomerase, oxidized glutathione, and reduced glutathione may be further mixed, and more preferably, molecular chapelone.
- the protein, disulfide bond isomerase and oxidized glutathione are further mixed.
- at least one substance selected from the group consisting of a molecular chaperone protein and a disulfide bond isomerase may be further mixed.
- a dimer IgA antibody and a monomeric IgA antibody or a dimer IgA antibody, a monomeric IgA antibody, and an SC, or a dimeric IgA antibody, a monomeric IgA antibody, and a molecular chapelon.
- Mixing of at least one substance selected from the group consisting of oxidized glutathione and reduced glutathione may be carried out in a buffer solution adjusted to pH 6 to 10, preferably pH 7 to 8.
- the buffer solution include, but are not limited to, a phosphate buffer solution, a Tris-hydrochloric acid buffer solution, a Good's buffer solution, and the like.
- An appropriate temperature at the time of mixing can be appropriately determined by those skilled in the art, and is, for example, 25 ° C. to 45 ° C., preferably 30 ° C. to 43 ° C., more preferably 35 ° C. to 40 ° C., for example, around 37 ° C.
- the mixing time is not particularly limited and can be appropriately determined by those skilled in the art based on other conditions such as reaction volume, and is, for example, 6 hours or more, 12 hours or more, 24 hours or more, or 48 hours or more. It may be about 24 hours to 72 hours.
- the mixing ratio of dimer IgA antibody and monomeric IgA antibody is not particularly limited and can be appropriately determined by those skilled in the art.
- the trimeric and tetrameric IgA antibodies thus produced are separated from other IgA antibodies (dimeric IgA antibody and monomeric IgA antibody that have not been multimerized) based on their molecular size and other characteristics.
- the trimeric IgA antibody and the tetrameric IgA antibody can also be separated from each other.
- the production method of the present application may further include a step of separating the trimer IgA antibody and the tetramer IgA antibody from other IgA antibodies.
- trimer and tetramer IgA antibodies produced by the production method of the present application can be confirmed by a known method such as ELISA method, size exclusion chromatography, affinity chromatography and the like.
- Most of the multimeric IgA antibodies produced by the production method of the present application are tetrameric IgA antibodies. Therefore, according to the production method of the present application, a mixture of a trimeric IgA antibody and a tetrameric IgA antibody containing a higher proportion of the tetramer IgA antibody than the trimeric IgA antibody can be obtained.
- Multispecific Multimeric IgA Antibodies In a second aspect of the invention, at least double, comprising a first Fab region containing a first antigen binding site and a second Fab region containing a second antigen binding site. Specific trimeric or tetrameric IgA antibodies are provided (hereinafter, also referred to as “multispecific multimeric IgA antibodies of the present application”). As a further aspect of the multispecific multimeric IgA antibody of the present application, at least a dual, comprising a first Fab region containing a first antigen binding site, a second Fab region containing a second antigen binding site, and SC. Specific trimeric or tetrameric IgA antibodies are provided. The multispecific multimeric IgA antibody of the present application is preferably obtained by the above-mentioned production method of the present application.
- the multispecific multimeric IgA antibody is preferably a polymer of one dimeric IgA antibody and one or two monomeric IgA antibodies.
- the multispecific multimeric IgA antibody is more preferably a polymer of one dimeric IgA antibody, one or two monomeric IgA antibodies, and SC.
- one dimeric IgA antibody and one or two monomeric IgA antibodies are trimeric or tetrameric via SC.
- the dimeric IgA antibody comprises a first antigen binding site and the monomeric IgA antibody comprises a second antigen binding site.
- the multispecific multimeric IgA antibody of the present application comprises four first Fab regions and at least two second Fab regions.
- the multispecific multimeric IgA antibody of the present application comprises four first Fab regions, at least two second Fab regions, and SC.
- the multispecific multimeric IgA antibody of the present application is a bispecific trimeric IgA antibody containing four first Fab regions and two second Fab regions, or four first Fab regions.
- the multispecific multimeric IgA antibody of the present application is a bispecific trimeric IgA antibody containing four first Fab regions, two second Fab regions and SC, or four third.
- Bispecific tetramer IgA antibody containing 1 Fab region, 4 2nd Fab regions and SC, or 4 1st Fab regions, 2 2nd Fab regions, 2 3rd Fab regions And SC may be a trispecific tetrameric IgA antibody.
- the four first Fab regions are derived from a dimeric IgA antibody and the two or four second or third Fab regions are derived from a monomeric IgA antibody.
- the multispecific multimeric IgA antibody of the present application may be either IgA1 or IgA2, or may contain both.
- the multispecific multimeric IgA antibody of the present application may contain both IgA1 or IgA2.
- the multispecific multimeric IgA antibody may contain four Fab regions from the dimer IgA1 and two or four Fab regions from the monomeric IgA2.
- the IgA2 contained in the multispecific multimeric IgA antibody of the present application may be IgA2m1, IgA2m2, or IgA2 (n).
- the multispecific multimeric IgA antibody of the present application may have a hydrophobic amino acid at the 458th amino acid residue in the heavy chain constant region.
- hydrophobic amino acid examples include isoleucine, leucine, methionine, tryptophan, and glycine, and preferred examples include isoleucine.
- the multispecific multimeric IgA antibody of the present application may be a recombinant IgA antibody.
- the multispecific multimeric IgA antibody of the present application is a polymer of one dimeric IgA antibody and one or two monomeric IgA antibodies, or one dimeric IgA antibody and one.
- any or all of the dimeric IgA antibody and the monomeric IgA antibody may be recombinant IgA antibodies.
- the IgA antibody and SC constituting the multispecific multispecific IgA antibody of the present application are as described in "2. Method for producing multispecific IgA antibody" above.
- composition of the present application a pharmaceutical composition containing the multispecific multimeric IgA antibody of the present application is provided (hereinafter, also referred to as “pharmaceutical composition of the present application”).
- the pharmaceutical composition of the present application preferably contains the multispecific multimeric IgA antibody of the present application or a mixture of the multispecific multimeric IgA antibody as an active ingredient.
- the pharmaceutical composition of the present application can be used, for example, for the treatment, prevention, diagnosis, etc. of a disease.
- the target disease for which the pharmaceutical composition of the present application is used is not particularly limited, and examples thereof include infectious diseases, such as infectious diseases caused by pathogens such as parasites, bacteria, fungi, viruses, and abnormal prions, and malignant tumors. Further examples of infections include influenza virus infection, RS virus infection, Ebola virus infection, severe febrile thrombocytopenia syndrome (SFTS), severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), acquired. Mucosal infections such as immunodeficiency syndrome (AIDS) can be mentioned.
- the multispecific multimeric IgA antibody contained in the pharmaceutical composition of the present application has an antigen-binding site suitable for the purpose of use of the pharmaceutical composition.
- a multispecific multimeric IgA that specifically binds to two different proteins (for example, causative protein, marker protein, etc.) related to one target disease.
- Antibodies can be used.
- the multispecific multimeric IgA antibody contained in the pharmaceutical composition of the present application may specifically bind to the HA protein and NA protein of influenza virus, respectively.
- the multispecific multimeric IgA antibody contained in the pharmaceutical composition of the present application may specifically bind to a protein specific to a target cell and a protein effective for treatment.
- antigens or epitopes that can be targeted by the multispecific multimeric IgA antibody contained in the pharmaceutical composition of the present application include, but are not limited to, multiple epitopes of the Evolavirus glycoprotein and SFTS virus glycoprotein. Examples thereof include Gn protein and Gc protein, lymphocyte marker proteins such as CD3 and CD8, and cancer-specific antigens.
- the pharmaceutical composition of the present application can be formulated and administered in a dosage form such as a powder or a liquid.
- the pharmaceutical composition of the present application may further contain excipients, additives, thickeners and the like known in the pharmaceutical field.
- the pharmaceutical composition of the present application may be administered by spraying onto the nasal mucosa, administration by inhalation into the lower respiratory tract using a nebulizer, or the like.
- the pharmaceutical composition of the present application may be intended for humans, or non-human mammals such as domestic animals such as horses, cows, goats, sheep and pigs, pet animals such as dogs and cats, chimpanzees. , Gorilla, chimpanzee and other primates, mice, rats, guinea pigs and other rodents and the like.
- non-human mammals such as domestic animals such as horses, cows, goats, sheep and pigs, pet animals such as dogs and cats, chimpanzees. , Gorilla, chimpanzee and other primates, mice, rats, guinea pigs and other rodents and the like.
- any of the heavy chain, light chain, SC, and J chain of the multispecific multimeric IgA antibody contained in the pharmaceutical composition of the present application is derived from the target animal of the pharmaceutical composition (the target animal type). ) It is preferable to include an amino acid sequence. More preferably, the heavy chain, light chain, SC, and J chain of the multispecific multimeric IgA antibody contained in the pharmaceutical composition of the present application are all derived from the target animal of the pharmaceutical composition (target animal). Contains the amino acid sequence (which is the type).
- the target animal type means the IgA heavy chain and the IgA light chain of the target animal in which the constant region of the heavy chain and the light chain of the multispecific multimeric IgA antibody is the target.
- the target animal type means that the SC and J chains of the multispecific multimeric IgA antibody have the amino acid sequences of the SC and J chains of the target animal. do.
- the amino acid sequences of IgA heavy chain, IgA light chain, SC and J chain may contain mutations as long as they have the antigen-binding activity of interest.
- ⁇ 1 heavy chain which is a constant region of human IgA1
- HC ⁇ 1 heavy chain
- primer is a human IgA1 antibody constant using an appropriate primer set that amplifies the IgA1 antibody constant region containing sites recognized by the restriction enzymes XhoI and HindIII.
- the region gene was amplified by PCR.
- the PCR conditions were 98 ° C. for 10 seconds, 55 ° C.
- ⁇ 1HC which contains a site recognized by XhoI and HindIII and is an IgG1 antibody constant region excluding the signal sequence, is removed.
- PCR was performed with the appropriate primer set for this.
- the PCR conditions were 98 ° C. for 10 seconds, 55 ° C. for 5 seconds, and 72 ° C. for 30 seconds for 30 cycles.
- the PCR product was purified using MonoFas DNA Purification Kit I (GL Sciences Inc., Tokyo, Japan).
- the purified ⁇ 1HC and ⁇ 1HC were removed from the T.I.
- the expression vector of Tiller et al. was treated with XhoI (New England Biolabs) and HindIII-HF (New England Biolabs) at 37 ° C. with restriction enzymes.
- Purification of restriction enzyme products was performed using MonoFas DNA Purification Kit I.
- Ligation of restriction enzyme-treated DNA was performed using DNA Ligation Kit ⁇ Mighty Mix> (Thermo Fisher Scientific), and the entire amount was transformed into Competent Quick DH5 ⁇ at 42 ° C.
- the plasmid extraction was performed by PureYield TM plasmid Miniprep System (Promega).
- the extracted plasmid was sequenced using Applied Biosystems 3130 Genetic Analyzer.
- the sequencing reaction was carried out using the BigDye Terminator v3.1 Cycle Sequenceting Kit, and the purification was carried out by the BigDye Terminator TM Kit. As mentioned above, all the operations were carried out according
- the ⁇ 2m2 HC which is an allotype of human IgA2, is codon-optimized for humans from the sequences (Accession number, ⁇ 2m2 HC is M60192 and AJ012264) registered in IMGT / GENE-DB, and artificially synthesized (GeneArt Strings DNA). Fragments).
- ⁇ 2m2 HC is M60192 and AJ012264 registered in IMGT / GENE-DB, and artificially synthesized (GeneArt Strings DNA). Fragments).
- the codons of the last amino acid alanine in the variable region and the first amino acid serine in the constant region were reorganized to prepare a NheI cleavage site.
- F045-092 Cloning of antibody variable region genes into ⁇ 1, ⁇ 2m2 HC, and ⁇ LC expression vectors F045-092, known as an antibody clone that broadly binds to hemagglutinin (HA) of influenza virus (H3N2), was used. F045-092 is codon-optimized for humans using sequences registered in Nucleotide (Acclusion number has AB649270 for heavy chain and AB649271 for light chain), and ⁇ 1 HC (heavy chain) and ⁇ 2m2 HC (heavy chain), respectively. And ⁇ LC ( ⁇ chain) were adjusted so that they could be incorporated into an expression vector and artificially synthesized (GeneArt Strings DNA Fragments).
- PCR was performed using a primer set in which a recognition sequence for the restriction enzyme AgeI was added to the 5'and 3'ends and PrimeSTAR Max DNA Polymerase (Takara Bio) to specifically amplify the sequence of the fluorescent protein mCherry. .. Then, each IgA ⁇ mutant and mCherry were treated with restriction enzymes using the restriction enzyme AgeI (New England Biolabs) under the optimum conditions, and then subjected to agarose gel electrophoresis to digest the target product by the restriction enzymes. Only the band was recovered.
- AgeI New England Biolabs
- the plasmid DNA extraction was performed by PureYield plasmid Miniprep System (Promega), and the sequence sequence was analyzed by using the Sanger method.
- mCherry was added to the 5'side of the sequence encoding IgA1 ⁇ and IgA2m2 ⁇ .
- IgA ⁇ mutants fused with this fluorescent protein mCherry were used as mC-A1 antibody and mC-A2 antibody, respectively. All the operations performed followed the attached instructions.
- J chain and secretory component (SC) J chain (GenBank accession no. NM_144646) is artificially added with the XhoI recognition sequence and Kozak sequence on the 5'side of the coding sequence and the NotI recognition sequence on the 3'side. It was artificially synthesized by a gene synthesis service (Eurofin Genomics). Then, using XhoI (New England Biolabs) and NotI-HF (New England Biolabs), restriction enzyme treatment was performed under the optimum conditions, and the pCXSN vector, which is an expression vector for cultured mammalian cells under the same conditions, was also used. Restriction enzyme treatment was performed.
- Ligation of restriction enzyme-treated DNA was performed using DNA Ligation Kit ⁇ Mighty Mix> (Thermo Fisher Scientific), and a part of the DNA was transformed into Competent Quick DH5 ⁇ at 42 ° C.
- the plasmid extraction was performed by PureYield TM plasmid Miniprep System (Promega).
- the extracted plasmid was sequenced using Applied Biosystems 3130 Genetic Analyzer.
- the sequencing reaction was carried out using the BigDye Terminator v3.1 Cycle Sequenceting Kit, and the purification was carried out by the BigDye Terminator TM Kit. As mentioned above, all the operations were carried out according to the attached manual.
- the wild-type SC uses 1809 bp (including the signal sequence) from the 5'end of pIgR (GenBank accession no. NM_002644), and the XhoI recognition sequence and the kozak sequence, 3 on the 5'side of the SC sequence.
- a DNA fragment (SEQ ID NO: 7) containing a Hind III recognition sequence, a Trombin cleavage sequence, and 6x His tag on the'side was artificially synthesized using GeneArt® Strings DNA Fragments (Life Technologies). The synthesized DNA fragment was subjected to PCR using PrimeSTAR Max DNA Polymerase (Takara Bio, Kusatsu, Japan) to purify the DNA.
- restriction enzyme treatment was performed using XhoI and HindIII under the optimum conditions, and the pCXSN vector, which is an expression vector for cultured mammalian cells, was also treated with restriction enzymes under the same conditions.
- Ligation of restriction enzyme-treated DNA was performed using DNA Ligation Kit ⁇ Mighty Mix> (Thermo Fisher Scientific), and a part of the DNA was transformed into Competent Quick DH5 ⁇ at 42 ° C.
- the plasmid extraction was performed by PureYield TM plasmid Miniprep System (Promega). The extracted plasmid was sequenced using Applied Biosystems 3130 Genetic Analyzer.
- the sequencing reaction was carried out using the BigDye Terminator v3.1 Cycle Sequenceting Kit, and the purification was carried out by the BigDye Terminator TM Kit. As mentioned above, all the operations were carried out according to the attached manual. All the operations performed followed the attached instructions.
- the gene sequence encoding SC-wt is shown in Figure 2-2.
- the purified DNA fragment was phosphorylated using T4 polynucleotide kinase (Takara Bio, Kusatsu, Japan), and was ring-shaped by T4 DNA ligase (Takara Bio, Kusatsu, Japan).
- T4 polynucleotide kinase Takara Bio, Kusatsu, Japan
- T4 DNA ligase Takara Bio, Kusatsu, Japan
- the plasmid DNA SEQ ID NO: 8 encoding the cyclized deletion mutant was subjected to E. coli.
- COL DH5 ⁇ Competent Cells (Takara Bio, Kusatsu, Japan) were transformed at 42 ° C.
- Plasma DNA extraction was performed by PureYield plasmid Miniprep System. The extracted plasmid was sequenced using Applied Biosystems 3130 Genetic Analyzer.
- the sequencing reaction was carried out using the BigDye Terminator v3.1 Cycle Sequenceting Kit, and the purification was carried out by the BigDye Terminator TM Kit. As mentioned above, all the operations were carried out according to the attached manual. All the operations performed followed the attached instructions.
- the gene sequence encoding the SC12 deletion mutant is shown in FIG. 2-3.
- the constituent molecules of the monomeric IgA antibody are heavy chain and light chain, and the dimeric IgA antibody is composed of heavy chain, light chain and J chain. ..
- the plasmid DNA expressing the molecules constituting the monomer and dimeric IgA antibody was added to Expi293F human cell (Thermo Fisher Scientific) 2.9 x 10 6 cells / mL, which is a mammalian cultured cell derived from human kidney cells. They were co-introduced using the Expression System Kit (Thermo Fisher Scientific, Western, plasmid, USA). Then, the cells were cultured with shaking at 37 ° C., 8% CO 2 , and 120 rpm, and the cell culture solution was collected one week later.
- mC-A1 and mC-A2 antibodies Since the mC-A1 and mC-A2 antibodies do not have a light chain, the plasmid DNA encoding each heavy chain and J chain can be fed from human kidney cells, respectively.
- Expi293F human cell (Thermo Fisher Scientific) 2.9 x 10 6 cells / mL was introduced with Expi293 Expression System Kit (Thermo Fisher Scientific) using cultured cells. Then, the cells were cultured with shaking at 37 ° C., 8% CO 2 , and 120 rpm, and the cell culture solution was collected one week later.
- the recombinant IgA antibody and mC-A1 / 2 purified and recovered cell culture solution were centrifuged at 3000 rpm for 20 minutes to remove debris such as cells, and only the culture supernatant was recovered. In addition, this centrifugation operation was performed twice in total. Then, the supernatant was filtered using a glass fiber filter and a stericup (Merck KGaA, Darmstadt, Germany). Purification of recombinant IgA antibody and mC-A1 / 2 was carried out using CaptureSelect IgA Infinity Matrix (Thermo Fisher Scientific), which specifically recognizes the constant region of human IgA antibody. The purification method was carried out according to the instructions.
- the purification method is briefly described below.
- the column is equilibrated with 10 CV PBS and the filtered culture supernatant is loaded onto the column.
- the column was washed with 10 CV PBS, the antibody was eluted with 5 CV 0.1 M Glycine-HCl (pH 3.0) and the eluate was neutralized with 1 M Tris-HCl (pH 8.0).
- Antibody enrichment was performed using Amicon® Ultra Centrifugal Filter Devices (Millipore) according to the instructions.
- the plasmid DNA encoding SC12 was added to Expi293F human cell (Thermo Fisher Scientific) 2.9x10 6 cells / mL, which is a mammalian cultured cell derived from human kidney cells. The gene was introduced using. Then, the cells were cultured with shaking at 37 ° C., 8% CO 2 , and 120 rpm, and the cell culture solution was collected one week later. Then, the collected cell culture solution was centrifuged at 3000 rpm for 20 minutes to remove debris such as cells, and only the culture supernatant was collected. In addition, this centrifugation operation was performed twice in total.
- SC12 in the culture supernatant was purified using an affinity column packed with Ni Sepharose excel (GE Healthcare) that recognizes the C-terminal His tag of each protein.
- the equilibrium solution is 20 mM sodium phosphate, 0.5 M NaCl, pH 7.4
- the wash solution is 20 mM sodium phosphate, 0.5 M NaCl, 10 mM imidazole, pH 7.4
- the eluent is 20 mM sodium phosphate, 0.5 M NaCl, 500 mM imidazole, pH 7.4 was used.
- the equilibration solution was passed through 5 CV (column volume) to equilibrate the column, and then the culture supernatant was passed through.
- Example 1 Extracellular IgA antibody formation
- HC heavy chains
- LC light chains
- JC J chains
- SC co-expressing
- the IgA antibody's ability to promote trimeric and tetramer formation possessed by this SC is the trimeric and tetramer IgA antibody (Tri /) formed by the interaction of four types of proteins coexisting in the cell. It was evaluated by measuring Tet IgA). Therefore, it was evaluated whether SC functions as a promoter of multimeric IgA antibody formation from each isolated protein produced from different cells under extracellular conditions rather than the intracellular environment.
- SC12 composed of domains 1 and 2 of SC was shown to have higher intracellular trimer and tetramer formation promoting ability than SC-wt, in this example, it was designated as SC. SC12 was used.
- the HPLC system used was Agilent 1260 Infinity (Agilent Technologies), and the column used was KW404-4F (shodex).
- a phosphate buffer pH 7.4 was used as the eluent, and the flow rate was 0.2 mL / min.
- 9 ⁇ L of each IgA antibody mixture was used.
- the chromatogram was analyzed using OpenLAB CDS ChemStation Edition (Agilent Technologies).
- mA1 + dA1 + SC12 indicates the result of mixing the monomeric IgA antibody, the dimer IgA antibody, and SC12.
- MA1 + SC12 indicates the result of mixing the monomeric IgA antibody and SC12.
- DA1 + SC12 indicates the result of mixing the dimer IgA antibody and SC12.
- trimer / tetramer IgA antibody can be formed extracellularly as well as intracellularly. Furthermore, it was shown that the monomers and dimers do not polymerize with each other. Therefore, it was found that the trimer / tetramer IgA antibody is formed by the polymerization of the dimer IgA antibody and the monomeric IgA antibody.
- Example 2 Comparison of multimeric IgA antibody formation in the presence of SC12 and SC-wt
- a multimeric IgA antibody was formed by mixing SC, a monomer, and a dimeric IgA antibody extracellularly, indicating that SC contributes to the formation of the multimeric IgA antibody. ..
- previous studies by the inventors have shown that SC12 has a higher ability to promote trimer / tetramer formation than SC-wt under intracellular conditions. Therefore, in order to search for a method for efficiently producing a trimer / tetramer IgA antibody under extracellular conditions, the tetramer formation promoting ability of SC12 and SC-wt was compared.
- the trimer / tetramer IgA produced in the reaction solution was detected by the ELISA method.
- the ELISA method was performed as follows. 50 ⁇ l of recombinant HA (derived from A / Sydney / 5/1997 (H3N2), 5 ⁇ g HA / mL) was immobilized overnight at 4 ° C. on a 96-well half plate, and then 1% BSA-PBS was added to room temperature for 1 hour. Blocking was performed. Then, a 3-fold serial dilution series of 200-fold diluted antibody samples was prepared, added to each well, and reacted at 37 ° C. for 2 hours.
- the IgA antibodies used in this experiment are mC-A1 and IgA antibodies having a Fab region containing the variable region of F045-092, and these antibodies have the same constant region but different variable regions. That is, the method for producing a multimeric IgA antibody of the present application is a variable region-independent type, and it is possible to produce a double or more specificity, preferably a double or triple specificity IgA antibody having different specificities. Furthermore, it was shown that even if the dimer IgA antibody and the monomeric IgA antibody have different variable regions, the multimer IgA antibody can be formed.
- Example 3 Identification of factors involved in promoting multimer formation 1
- Example 2 revealed that SC12 has a higher ability to promote multimer formation of IgA antibody than SC-wt. Therefore, in order to further enhance multimer formation, the addition of protein components other than SC and IgA antibodies was examined.
- the final concentrations of SC12, SC-wt, mA1 and dA1 and mC-mA1 and mC-dA1 prepared as described above were 0.5 mg / mL, respectively, and the additive (Suple) was added to a phosphate buffer solution (pH 7.4). It was mixed in and reacted at 37 ° C. for 6 hours using a rotator. Supple contains chaperone proteins DnaK Mix (5 ⁇ M DnaK, 1 ⁇ M DnaJ, 1 ⁇ M GrpE) and GroE Mix (0.5 ⁇ M GroEL, 1 ⁇ M GroES), disulfide bond isomerase DsbC (375 ⁇ g / mL), and oxidized glutathione. .. Trimer / tetramer IgA produced in the reaction solution was detected by the ELISA method in the same manner as in Example 2.
- FIGS. 5A and 5B The results are shown in FIGS. 5A and 5B.
- an increase in the OD value which is an index of trimer / tetramer IgA formation, was observed by adding Supple to both the mixed solution of "mA1 + mC-dA1" and "mC-mA1 + dA1".
- the OD value increased more than twice in both mixed solutions.
- the addition of Supple was found to significantly increase the OD value to the same extent as SC12 (Fig. 5B).
- Example 4 Identification of factors involved in promoting multimer formation 2
- the contribution of each factor to multimer formation was evaluated by reacting mC-mA1 and dA1 alone in the presence of SC12 with each of the four major constituent factors contained in Supple.
- the reaction and detection were carried out in the same manner as in Example 3 except that DnaK Mix, GroE Mix, GSSG, or DsbC was added alone as an additive.
- Example 5 Identification of factors involved in promoting multimer formation 3
- IgA antibodies are classified into two subclasses, IgA1 and IgA2, according to the difference in constant region, and IgA2 is further divided into three allotypes, IgA2m1, IgA2m2, and IgA2 (n).
- Patent Document 1 the efficiency of trimer / tetramer IgA antibody formation was different under intracellular conditions due to the difference in these constant regions.
- the mC-A1 and mC-A2 prepared as described above were reacted by adding SC12 to the combination of the monomer and the dimer IgA antibody in the same manner as in Example 3, and then adding Supple to react, and then the trimer / Tetramer IgA formation was evaluated.
- Example 6 Identification of factors involved in promoting multimer formation 4
- the reaction time was examined as a factor affecting the multimerization of IgA antibody.
- mC-mA1 and dA1 were reacted in phosphate buffer (pH 7.4) at 37 ° C. Samples were collected 6 hours, 12 hours, and 24 hours after the start of the reaction and evaluated for trimer / tetramer IgA formation by ELISA.
- Example 7 Evaluation of bispecific IgA antibody using different subtypes of HA
- Example 2 by mixing the monomer and dimer of the mCherry fusion IgA antibody in the presence of SC-wt and SC12, a trimer / tetramer IgA antibody with different variable regions is formed. It revealed that. Furthermore, in Example 5, the difference in multimer formation efficiency due to the difference in the subclass of IgA antibody was also clarified. Therefore, in this example, a trimer formed by the method of the present application using two types of influenza virus protein HA with different subtypes to which a detection tag is added and an IgA antibody clone having specificity for each HA. The bispecificity of the / tetrameric IgA antibody was verified.
- H1 and H3 which are antibody clones having specificity for H1 and H3 subtypes of influenza A. These clones were isolated from subjects in clinical trials of the nasal influenza vaccine.
- the variable regions derived from these antibodies were cloned into the expression vectors of ⁇ 1 HC, ⁇ 2m2 HC, and ⁇ LC by the same method as described above, and converted into influenza virus A / California / 7/2009 (H1N1) (H1 / HA).
- Antibodies and dimeric IgA1 antibodies were prepared.
- the gene sequence of the heavy chain variable region of 18-18K (H1) is shown in SEQ ID NO: 9
- the amino acid sequence is shown in SEQ ID NO: 10
- the gene sequence of the light chain variable region is shown in SEQ ID NO: 11
- the amino acid sequence is shown in SEQ ID NO: 12.
- the gene sequence of the heavy chain variable region of 15-19L (H3) is shown in SEQ ID NO: 13
- the amino acid sequence is shown in SEQ ID NO: 14
- the gene sequence of the light chain variable region is shown in SEQ ID NO: 15
- the amino acid sequence is shown in SEQ ID NO: 16.
- SC and SC12 were also prepared as described above.
- the reaction was carried out at 37 ° C. for 12 hours using a thermal cycler. Trimer / tetramer IgA produced in the reaction solution was detected by the ELISA method.
- the ELISA method was performed as follows. Recombinant H3 / HA-Strept (A / New York / 39/2012 (H3N2) derived, 5 ⁇ g HA / mL) with 40 ⁇ l strept tag added to a 384-well plate was solid-phased at 4 ° C. overnight and then 1% BSA. -PBS was added and blocking was performed at room temperature for 1 hour. Then, a 2-fold serial dilution series of 100-fold diluted antibody samples was prepared, added to each well, and reacted at 37 ° C. for 2 hours.
- H1 / HA-His (derived from A / California / 7/2009 (H1N1), 1 ⁇ g HA / mL) with a 40 ⁇ l His tag added was added to each well and reacted at 37 ° C. for 1 hour. I let you.
- 40 ⁇ l of 6000-fold diluted mAb-HRP-DirecT (MBL) was added to each well and reacted at 37 ° C. for 1 hour.
- a color reaction was carried out using Immobilon Western Chemilum HRP Substrate (MERCK), and the absorbance at a wavelength of 450 nm was measured.
- MERCK Immobilon Western Chemilum HRP Substrate
- SEQ ID NO: 1 Amino acid sequence of IgA1 constant region SEQ ID NO: 2; Amino acid sequence of IgA2m2 constant region SEQ ID NO: 3; Amino acid sequence of wild-type SC SEQ ID NO: 4; Amino acid sequence of SC12 SEQ ID NO: 5; Amino acid sequence of wild-type SC containing signal sequence, thrombin site, His tag SEQ ID NO: 6; Amino acid sequence of SC12 containing signal sequence, thrombin site, His tag SEQ ID NO: 7; Nucleotide sequence of wild-type SC containing signal sequence, thrombin site, His tag SEQ ID NO: 8; Nucleotide sequence of SC12 containing signal sequence, thrombin site, His tag SEQ ID NO: 9; Nucleotide sequence of heavy chain variable region of 18-18K (H1 specific) SEQ ID NO: 10; Amino acid sequence of heavy chain variable region of 18-18K (H1 specific) SEQ ID NO: 11; Nucleotide
Abstract
Description
[1]二量体IgA抗体、及び単量体IgA抗体を混合することを含む、三量体及び四量体IgA抗体を製造するための方法、
[2]さらに分泌片を混合することを含む、[1]記載の方法、
[3]前記二量体IgA抗体が第1の抗原結合部位を含み、前記単量体IgA抗体が第2の抗原結合部位を含む、少なくとも二重特異性の三量体及び四量体IgA抗体が製造される、[1]又は[2]記載の方法、
[4]第3の抗原結合部位を含む別の単量体IgA抗体をさらに混合する、[3]記載の方法、
[5]前記二量体IgA抗体の4つのFab領域がそれぞれ第1の抗原結合部位を含み、前記第2の抗原結合部位を含む単量体IgA抗体の2つのFab領域がそれぞれ第2の抗原結合部位を含む、[3]記載の方法、
[6]前記二量体IgA抗体の4つのFab領域がそれぞれ第1の抗原結合部位を含み、前記第2の抗原結合部位を含む単量体IgA抗体の2つのFab領域がそれぞれ第2の抗原結合部位を含み、前記別の単量体IgA抗体の2つのFab領域がそれぞれ第3の抗原結合部位を含む、[4]記載の方法、
[7]前記分泌片が野生型SC又はSC変異体である、[2]~[6]のいずれか1項記載の方法、
[8]分子シャペロンタンパク質、ジスルフィド結合イソメラーゼ、酸化型グルタチオン、及び還元型グルタチオンからなる群から選択される少なくとも1つの物質をさらに混合することを含む、請求項[1]~[7]のいずれか1項記載の方法、
[9]前記二量体IgA抗体及び前記単量体IgA抗体がそれぞれ別々に培養細胞で作製された組換えIgA抗体である、[1]~[8]のいずれか1項記載の方法、
[10]製造された三量体IgA抗体及び四量体IgA抗体を他のIgA抗体から分離することをさらに含む、[1]~[9]のいずれか1項記載の方法、
[11]製造された三量体IgA抗体と四量体IgA抗体を分離することをさらに含む、[10]記載の方法。
[12]第1の抗原結合部位を含む第1のFab領域、及び第2の抗原結合部位を含む第2のFab領域を含む、少なくとも二重特異性の三量体又は四量体IgA抗体、
[13]さらに分泌片を含む、[12]記載の抗体、
[14]第1の抗原結合部位を含む二量体IgA抗体1分子と、第2の抗原結合部位を含む単量体IgA抗体1分子又は2分子との重合物である、[12]記載の抗体、
[15]第1の抗原結合部位を含む二量体IgA抗体1分子と、第2の抗原結合部位を含む単量体IgA抗体1分子又は2分子と、分泌片との重合物である、[13]記載の抗体、
[16]4つの第1のFab領域、及び少なくとも2つの第2のFab領域を含む、[12]~[15]のいずれか1項記載の抗体、
[17]前記分泌片が野生型SC又はSC変異体である、[13]、[15]および[16]のいずれか1項記載の抗体、および
[18][12]~[17]のいずれか1項記載の抗体を含む医薬組成物
を提供する。
本明細書において使用される用語は、特に定義されない限り、当該技術分野で一般に使用される意味を有する。
本発明の第一の態様において、二量体IgA抗体、及び単量体IgA抗体を混合することを含む、三量体及び四量体IgA抗体の製造方法が提供される(以下、「本願の製造方法」ともいう)。本願の製造方法のさらなる態様として、二量体IgA抗体、単量体IgA抗体、及びSCを混合することを含む、三量体及び四量体IgA抗体の製造方法が提供される。本願の製造方法によれば、1つの二量体IgA抗体と、2つの単量体IgA抗体とが重合して、1つの四量体IgA抗体が製造される。さらに、本願の製造方法によれば、1つの二量体IgA抗体と、2つの単量体IgA抗体と、SCとが重合して、1つの四量体IgA抗体が製造される(図1)。また、本願の製造方法によれば、1つの二量体IgA抗体と、1つの単量体IgA抗体とが重合して、1つの三量体IgA抗体が製造される。またさらに、本願の製造方法によれば、1つの二量体IgA抗体と、1つの単量体IgA抗体と、SCとが重合して、1つの三量体IgA抗体が製造される。
本発明の第二の態様において、第1の抗原結合部位を含む第1のFab領域、及び第2の抗原結合部位を含む第2のFab領域を含む、少なくとも二重特異性の三量体又は四量体IgA抗体が提供される(以下、「本願の多重特異性多量体IgA抗体」ともいう)。本願の多重特異性多量体IgA抗体のさらなる態様として、第1の抗原結合部位を含む第1のFab領域、第2の抗原結合部位を含む第2のFab領域、及びSCを含む、少なくとも二重特異性の三量体又は四量体IgA抗体が提供される。本願の多重特異性多量体IgA抗体は、好ましくは、上記した本願の製造方法によって得られる。
本発明の第三の態様において、本願の多重特異性多量体IgA抗体を含む医薬組成物が提供される(以下、「本願の医薬組成物」ともいう)。本願の医薬組成物は、好ましくは、本願の多重特異性多量体IgA抗体、又は該多重特異性多量体IgA抗体の混合物を有効成分として含む。
1.IgA発現プラスミドベクターの作製
ヒトIgA1の定常領域であるα1重鎖(HC)の発現ベクターは下記の通り作製した。PCRはPrimeSTARTM(登録商標) MAX DNA Polymerase(Takara Bio, Kusatsu, Japan)を使用して、実施した。簡潔に記述すると、鋳型としてpFUSE-CHIg-hA1 (InvivoGen)、プライマーは制限酵素であるXhoIとHindIIIが認識するサイトを含むIgA1抗体定常領域を増幅する適切なプライマーセットを用いて、ヒトIgA1抗体定常領域遺伝子をPCRを行い増幅した。PCR条件は98℃ 10秒、55℃ 5秒、72℃ 10秒で30サイクルで実施した。続いて、T. Tillerら(J Immunol Methods, 329, 112-24, 2008)が報告したヒトγ1HCの発現ベクターを鋳型とし、XhoIとHindIIIが認識するサイトを含み、シグナル配列を除くIgG1抗体定常領域であるγ1HCを除去するための適切なプライマーセットを用いてPCRを実施した。PCR条件は98℃ 10秒、55℃ 5秒、72℃ 30秒で30サイクルで実施した。PCR産物の精製はMonoFas DNA精製キットI(GL Sciences Inc., Tokyo, Japan)を用いて行った。精製されたα1HCとγ1HCを除去したT. Tillerらの発現ベクターはXhoI (New England Biolabs)、HindIII-HF (New England Biolabs)を用いて37℃で制限酵素処理した。制限酵素産物の精製は、MonoFas DNA精製キットIを用いて行った。制限酵素処理したDNAのライゲーションはDNA Ligation Kit <Mighty Mix>(Thermo Fisher Scientific)を使用して行い、全量をCompetent Quick DH5αへ42℃で形質転換した。プラスミド抽出はPureYieldTM Plasmid Miniprep System(Promega)により行った。抽出したプラスミドはApplied Biosystems 3130 Genetic Analyzerを用いてシークエンスを実施した。シークエンス反応はBigDye Terminator v3.1 Cycle Sequencing Kitを用いて行い、精製はBigDye XTerminatorTM Kitにより行った。以上、全ての操作は添付の説明書に従い実施した。
インフルエンザウイルス(H3N2)のヘマグルチニン(HA)に対して広域に結合する抗体クローンとして知られているF045-092を使用した。F045-092はNucleotideに登録されている配列(Accession numberは重鎖がAB649270, 軽鎖がAB649271)をヒト用にコドン最適化を行い、それぞれα1 HC(重鎖)、α2m2 HC(重鎖)、及びλ LC(λ鎖)の発現ベクターへ組み込めるように調整し人工合成した(GeneArt Strings DNA Fragments)。AgeI-HF(全ての鎖)及び NheI-HF(重鎖)、XhoI(λ鎖)(New England Biolabs)で処理した合成配列と、同一の制限酵素で処理したα1 HC、α2m2 HC、及びλLCの発現ベクターは、MonoFas DNA精製キットIを用いて精製した。制限酵素処理したDNAのライゲーションはDNA Ligation Kit <Mighty Mix>(Thermo Fisher Scientific)を使用して行い、一部をCompetent Quick DH5αへ42℃で形質転換した。プラスミド抽出はPureYieldTM Plasmid Miniprep System(Promega)により行った。抽出したプラスミドはApplied Biosystems 3130 Genetic Analyzerを用いてシークエンスを実施した。シークエンス反応はBigDye Terminator v3.1 Cycle Sequencing Kitを用いて行い、精製はBigDye XTerminatorTM Kitにより行った。以上、全ての操作は添付の説明書に従い実施した。
IgA抗体の異なるサブクラスであるα1及びα2m2の重鎖における241番目のシステインまでを欠損させたCH2及びCH3から構成されたIgA1Δ及びIgA2m2Δ変異体を、制限酵素サイトを付加した特異的プライマーセットとPrimeSTAR Max DNA Polymerase (Takara Bio, Kusatsu, Japan)を用いてPCRにより作出した。また、5’及び3’末端に制限酵素AgeIの認識配列を付加したプライマーセットとPrimeSTAR Max DNA Polymerase (Takara Bio)を用いてPCRを行い、蛍光タンパク質であるmCherryの配列を特異的に増幅させた。その後、各IgAΔ変異体、及びmCherryを制限酵素AgeI (New England Biolabs)を用いて至適条件で制限酵素処理を実施した後、アガロースゲル電気泳動を行うことで、制限酵素によって消化された目的産物のバンドのみを回収した。回収した目的産物をMonoFas DNA精製キットI(GL Sciences Inc., Tokyo, Japan)を用いて精製し、その精製したIgAΔ変異体をコードしたDNA断片及び、mCherryをコードしたDNA断片を1:3 (= IgA1Δ: mCherry)で混合し、等量のDNA Ligation Kit <Mighty Mix> (Thermo Fisher Scientific)を加え、16℃で30分反応させライゲーションを行った。環化されたIgAΔとmCherryをE. coli DH5α Competent Cells (Takara Bio, Kusatsu, Japan)に42℃で形質転換した。プラスミドDNA抽出は、PureYield Plasmid Miniprep System(Promega)により行い、サンガー法を用いてシークエンス配列の解析を行った。mCherryは、IgA1Δ及びIgA2m2Δをコードする配列の5’側に付加した。また、この蛍光タンパク質mCherryが融合したIgAΔ変異体をそれぞれmC-A1抗体、並びにmC-A2抗体とした。実施した操作は全て添付された説明書に従った。
J鎖(GenBank accession no. NM_144646)を、コーディング配列の5’側にXhoI認識配列及びKozak配列を、さらに3’側にNotI認識配列を付加したものを人工遺伝子合成サービス(ユーロフィンジェノミクス)により人工合成した。その後、XhoI(New England Biolabs)及びNotI-HF(New England Biolabs)を用いて、至適の条件で制限酵素処理を実施し、同一の条件で哺乳類培養細胞用の発現ベクターであるpCXSNベクターもまた制限酵素処理を実施した。制限酵素処理したDNAのライゲーションはDNA Ligation Kit <Mighty Mix>(Thermo Fisher Scientific)を使用して行い、一部をCompetent Quick DH5αへ42℃で形質転換した。プラスミド抽出はPureYieldTM Plasmid Miniprep System(Promega)により行った。抽出したプラスミドはApplied Biosystems 3130 Genetic Analyzerを用いてシークエンスを実施した。シークエンス反応はBigDye Terminator v3.1 Cycle Sequencing Kitを用いて行い、精製はBigDye XTerminatorTM Kitにより行った。以上、全ての操作は添付の説明書に従い実施した。
5つのドメインを持つSCを鋳型として、特異的なプライマーとPrimeSTAR Max DNA Polymerase (Takara Bio, Kusatsu, Japan)を使用し、最適なプライマーセット及び塩基長を考慮し至適条件でPCRを行うことで、SCのドメイン1及び2をコードする配列を増幅させた。また、SCの各ドメインはBethらの先行研究(eLife, 5, e10640, 2016)に従って決定した。PCR反応後、アガロースゲル電気泳動を行い、目的の塩基長が特異的に増幅されていることを確認し、PCR産物をMonoFas DNA精製キットI(GL Sciences Inc., Tokyo, Japan)を用いて、DNA精製を行った。また、精製したDNAフラグメントは、T4 polynucleotide kinase(Takara Bio, Kusatsu, Japan)を用いてリン酸化し、T4 DNA ligase(Takara Bio, Kusatsu, Japan)により環状にセルフライゲーションさせた。ライゲーションの操作が終了後、環化された欠失変異体をコードしたプラスミドDNA(配列番号8)をE. coli DH5α Competent Cells(Takara Bio, Kusatsu, Japan)に42℃で形質転換した。プラスミドDNA抽出はPureYield Plasmid Miniprep Systemにより行った。抽出したプラスミドはApplied Biosystems 3130 Genetic Analyzerを用いてシークエンスを実施した。シークエンス反応はBigDye Terminator v3.1 Cycle Sequencing Kitを用いて行い、精製はBigDye XTerminatorTM Kitにより行った。以上、全ての操作は添付の説明書に従い実施した。実施した操作は全て添付された説明書にしたがった。SC12欠失変異体をコードする遺伝子配列を図2-3に示す。
単量体IgA抗体の構成分子は重鎖、軽鎖であり、二量体IgA抗体は重鎖、軽鎖、J鎖から構成されている。単量体及び二量体IgA抗体を構成する分子を発現するプラスミドDNAを、ヒト腎臓細胞由来の哺乳培養細胞であるExpi293F human cell (Thermo Fisher Scientific) 2.9 x 106 cells/mLに、Expi293 Expression System Kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA)を用いて、それぞれ共導入した。その後、37℃、8% CO2、120rpmで振盪培養を行い、一週間後に細胞培養液を回収した。
mC-A1及びmC-A2抗体は、軽鎖を有していないため、各重鎖とJ鎖をコードしたプラスミドDNAをそれぞれ、ヒト腎臓細胞由来の哺乳培養細胞であるExpi293F human cell (Thermo Fisher Scientific) 2.9 x 106 cells/mLにExpi293 Expression System Kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA)を用いて、共導入した。その後、37℃、8% CO2、120rpmで振盪培養を行い、一週間後に細胞培養液を回収した。
回収した細胞培養液を、3000rpmで20分間の遠心分離により細胞などのデブリを取り除き、培養上清のみを回収した。また、この遠心の操作は計2回行った。その後、グラスファイバーフィルター及びステリカップ(Merck KGaA, Darmstadt, Germany)を用いて、上清のろ過を行った。組換えIgA抗体、及びmC-A1/2の精製はヒトIgA抗体の定常領域を特異的に認識するCaptureSelect IgA Affinity Matrix(Thermo Fisher Scientific)を用いて実施した。精製方法は説明書に従い実施した。簡潔に精製方法を以下に記述する。カラムは10CVのPBSで平衡化され、濾過した培養上清をカラムにロードする。10CVのPBSでカラムを洗浄し、5CVの0.1M Glycine-HCl(pH 3.0)で抗体を溶出し、溶出液は1M Tris-HCl (pH 8.0)で中和した。抗体の濃縮はAmicon(登録商標)Ultra Centrifugal Filter Devices(Millipore)を用いて、説明書に従って実施した。
単量体及び二量体IgA抗体の濃縮後、ゲル濾過クロマトグラフィーにより分画した。組換えIgA抗体の分画には、Superose6 10/300 GL(GE Healthcare)を用いて、また、mC-A1/2はSuperose 12 10/300 GLを用いて、説明書に従ってゲル濾過クロマトグラフィーを実施した。クロマトグラフィーの条件は、PBSを流速0.5mL/分、カラム平衡化1.5 CV、溶出0.2 mL/Fraction(計1.5 CV)で実施した。単量体、及び二量体IgA抗体を含むフラクションをAmicon(登録商標)Ultra Centrifugal Filter Devicesを用いて濃縮した。濃度はNanoDropで測定した。
SC12をコードするプラスミドDNAを、ヒト腎臓細胞由来の哺乳培養細胞であるExpi293F human cell(Thermo Fisher Scientific)2.9x106cells/mLにExpi293 Expression System Kit(Thermo Fisher Scientific)を用いて、遺伝子導入した。その後、37℃、8% CO2、120rpmで振盪培養を行い、一週間後に細胞培養液を回収した。その後、回収した細胞培養液を3000rpmで20分間の遠心分離により細胞などのデブリを取り除き、培養上清のみを回収した。また、この遠心の操作は計2回行った。培養上清中のSC12は、各タンパク質のC末端側のHisタグを認識するNi Sepharose excel(GE Healthcare)が充填されたアフィニティカラムを用いて精製した。簡潔に記述すると、平衡化溶液は20mMリン酸ナトリウム、0.5M NaCl、pH7.4、洗浄液は20mMリン酸ナトリウム、0.5M NaCl、10mMイミダゾール、pH7.4、溶出液は20mMリン酸ナトリウム、0.5M NaCl、500mMイミダゾール、pH7.4を使用した。平衡化溶液5CV(カラム体積)を通し、カラムの平衡化をした後、培養上清を通した。洗浄は、洗浄液20CVで行い、溶出は溶出液5CVで実施し、平衡化溶液5CVで再平衡化した。SC12の濃縮はAmicon(登録商標)Ultra Centrifugal Filter Devices(Millipore)を用いて、説明書に従って実施した。
発明者らの先行研究(特許文献1)により、三量体及び四量体分泌型IgA抗体(tSIgA)を構成する重鎖(HC)と軽鎖(LC)、J鎖(JC)及び分泌片(SC)を哺乳類培養細胞へ共発現させることで、効率良くtSIgAが産生されることが明らかにされた。さらに、SCの有無によってtSIgAの形成効率に差があることから、SCは培養細胞内においてIgA抗体の三量体及び四量体形成の促進因子として機能していることが示唆された。このSCが有するIgA抗体の三量体及び四量体形成促進能は、細胞内に共在した4種類のタンパク質が相互作用することで形成された三量体及び四量体IgA抗体(Tri/Tet IgA)を測定することで評価された。そこで、細胞内という限定的な環境ではなく、細胞外条件において、SCが、別々の細胞から産生された各単離タンパク質からの多量体IgA抗体形成の促進因子として機能するかを評価した。なお、SCのドメイン1及び2から構成されるSC12は、細胞内における三量体及び四量体形成促進能がSC-wtよりも高いことが示されたことから、本実施例では、SCとしてSC12を用いた。
実施例1により、細胞外において、SC、単量体及び二量体IgA抗体を混合することにより多量体IgA抗体が形成したことから、SCは多量体IgA抗体形成に寄与することが示された。また、発明者らの以前の研究では、細胞内条件においてSC-wtと比べ、SC12は三量体/四量体形成促進能が高いことが示された。そこで、細胞外条件において効率良く三量体/四量体IgA抗体を産生する方法を探索するために、SC12とSC-wtの四量体形成促進能を比較した。
実施例2により、SC12は、SC-wtと比べて、IgA抗体の多量体形成促進能が高いことが明らかになった。そこで、更に多量体形成を増強させるためにSC及びIgA抗体以外のタンパク質成分添加の検討を行った。
Suppleに含まれる4つの大きな構成因子をそれぞれ単独でSC12の存在下でmC-mA1とdA1を反応させることで、各因子の多量体形成への寄与を評価した。反応および検出は、添加剤としてDnaK Mix、GroE Mix、GSSG、またはDsbCを単独で添加する以外は実施例3と同様に行った。
IgA抗体の多量体化に寄与する因子として、IgA抗体の定常領域に着眼した。IgA抗体は、定常領域の違いによりIgA1とIgA2の2つのサブクラスに分類され、さらにIgA2はIgA2m1、IgA2m2、IgA2(n)の3つのアロタイプに分けられる。発明者らの先行研究(特許文献1)では、これらの定常領域の違いにより、細胞内条件において三量体/四量体IgA抗体形成効率が異なった。そこで、細胞外条件においても同様にIgA抗体サブクラスの違いにより多量体形成効率に差が認められるかを評価した。すなわち、IgA抗体の定常領域の違いによる多量体形成効率を、異なるサブクラスであるIgA1とIgA2m2を用いて比較した。
IgA抗体の多量体化に与える因子として、反応時間の検討を実施した。SC12及びSuppleの存在下で、mC-mA1とdA1をリン酸緩衝液(pH7.4)中、37℃で反応させた。反応開始の6時間、12時間、及び24時間後にサンプルを回収し、ELISA法にて、三量体/四量体IgA形成を評価した。
実施例2では、mCherry融合型IgA抗体の単量体及び二量体をSC-wt及びSC12の存在下で混合することにより、可変領域の異なる三量体/四量体IgA抗体が形成されることを明らかにした。更に、実施例5では、IgA抗体のサブクラスの違いによる多量体形成効率の違いについても明らかにした。そこで、本実施例では、検出タグを付加した亜型の異なる2種類のインフルエンザウイルスタンパク質HAと、それぞれのHAに特異性を有するIgA抗体クローンを用いて、本願の方法により形成された三量体/四量体IgA抗体の二重特異性を検証した。
SEQ ID NO:2; Amino acid sequence of IgA2m2 constant region
SEQ ID NO:3; Amino acid sequence of wild-type SC
SEQ ID NO:4; Amino acid sequence of SC12
SEQ ID NO:5; Amino acid sequence of wild-type SC containing signal sequence, thrombin site, His tag
SEQ ID NO:6; Amino acid sequence of SC12 containing signal sequence, thrombin site, His tag
SEQ ID NO:7; Nucleotide sequence of wild-type SC containing signal sequence, thrombin site, His tag
SEQ ID NO:8; Nucleotide sequence of SC12 containing signal sequence, thrombin site, His tag
SEQ ID NO:9; Nucleotide sequence of heavy chain variable region of 18-18K(H1 specific)
SEQ ID NO:10; Amino acid sequence of heavy chain variable region of 18-18K(H1 specific)
SEQ ID NO:11; Nucleotide sequence of light chain variable region of 18-18K(H1 specific)
SEQ ID NO:12; Amino acid sequence of light chain variable region of 18-18K(H1 specific)
SEQ ID NO:13; Nucleotide sequence of heavy chain variable region of 15-19L(H3 specific)
SEQ ID NO:14; Amino acid sequence of heavy chain variable region of 15-19L(H3 specific)
SEQ ID NO:15; Nucleotide sequence of light chain variable region of 15-19L(H3 specific)
SEQ ID NO:16; Amino acid sequence of light chain variable region of 15-19L(H3 specific)
Claims (18)
- 二量体IgA抗体、及び単量体IgA抗体を混合することを含む、三量体及び四量体IgA抗体を製造するための方法。
- さらに分泌片を混合することを含む、請求項1記載の方法。
- 前記二量体IgA抗体が第1の抗原結合部位を含み、前記単量体IgA抗体が第2の抗原結合部位を含む、少なくとも二重特異性の三量体及び四量体IgA抗体が製造される、請求項1又は2記載の方法。
- 第3の抗原結合部位を含む別の単量体IgA抗体をさらに混合する、請求項3記載の方法。
- 前記二量体IgA抗体の4つのFab領域がそれぞれ第1の抗原結合部位を含み、前記第2の抗原結合部位を含む単量体IgA抗体の2つのFab領域がそれぞれ第2の抗原結合部位を含む、請求項3記載の方法。
- 前記二量体IgA抗体の4つのFab領域がそれぞれ第1の抗原結合部位を含み、前記第2の抗原結合部位を含む単量体IgA抗体の2つのFab領域がそれぞれ第2の抗原結合部位を含み、前記別の単量体IgA抗体の2つのFab領域がそれぞれ第3の抗原結合部位を含む、請求項4記載の方法。
- 前記分泌片が野生型SC又はSC変異体である、請求項2~6のいずれか1項記載の方法。
- 分子シャペロンタンパク質、ジスルフィド結合イソメラーゼ、酸化型グルタチオン、及び還元型グルタチオンからなる群から選択される少なくとも1つの物質をさらに混合することを含む、請求項1~7のいずれか1項記載の方法。
- 前記二量体IgA抗体及び前記単量体IgA抗体がそれぞれ別々に培養細胞で作製された組換えIgA抗体である、請求項1~8のいずれか1項記載の方法。
- 製造された三量体IgA抗体及び四量体IgA抗体を他のIgA抗体から分離することをさらに含む、請求項1~9のいずれか1項記載の方法。
- 製造された三量体IgA抗体と四量体IgA抗体を分離することをさらに含む、請求項10記載の方法。
- 第1の抗原結合部位を含む第1のFab領域、及び第2の抗原結合部位を含む第2のFab領域を含む、少なくとも二重特異性の三量体又は四量体IgA抗体。
- さらに分泌片を含む、請求項12記載の抗体。
- 第1の抗原結合部位を含む二量体IgA抗体1分子と、第2の抗原結合部位を含む単量体IgA抗体1分子又は2分子との重合物である、請求項12記載の抗体。
- 第1の抗原結合部位を含む二量体IgA抗体1分子と、第2の抗原結合部位を含む単量体IgA抗体1分子又は2分子と、分泌片との重合物である、請求項13記載の抗体。
- 4つの第1のFab領域、及び少なくとも2つの第2のFab領域を含む、請求項12~15のいずれか1項記載の抗体。
- 前記分泌片が野生型SC又はSC変異体である、請求項13、15及び16のいずれか1項記載の抗体。
- 請求項12~17のいずれか1項記載の抗体を含む医薬組成物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3171544A CA3171544A1 (en) | 2020-03-23 | 2021-03-22 | Method for creating multimeric iga antibody, and multispecific multimeric iga antibody |
EP21774659.3A EP4130021A4 (en) | 2020-03-23 | 2021-03-22 | METHOD FOR PRODUCING A MULTIMER IGA ANTIBODY AND MULTI-SPECIFIC MULTIMER IGA ANTIBODIES |
KR1020227036654A KR20230005165A (ko) | 2020-03-23 | 2021-03-22 | 다량체 IgA 항체의 제조방법 및 다중특이성 다량체 IgA 항체 |
US17/906,956 US20230167199A1 (en) | 2020-03-23 | 2021-03-22 | METHOD FOR CREATING MULTIMERIC IgA ANTIBODY, AND MULTISPECIFIC MULTIMERIC IgA ANTIBODY |
CN202180023085.3A CN115397833A (zh) | 2020-03-23 | 2021-03-22 | 多聚体IgA抗体的制造方法与多特异性多聚体IgA抗体 |
JP2022510493A JPWO2021193553A1 (ja) | 2020-03-23 | 2021-03-22 | |
BR112022018985A BR112022018985A2 (pt) | 2020-03-23 | 2021-03-22 | Método para criar anticorpo iga multimérico, e anticorpo iga multimérico multiespecífico |
AU2021242058A AU2021242058A1 (en) | 2020-03-23 | 2021-03-22 | Method for creating multimeric IgA antibody, and multispecific multimeric IgA antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-051139 | 2020-03-23 | ||
JP2020051139 | 2020-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021193553A1 true WO2021193553A1 (ja) | 2021-09-30 |
Family
ID=77891893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/011753 WO2021193553A1 (ja) | 2020-03-23 | 2021-03-22 | 多量体IgA抗体の作製法及び多重特異性多量体IgA抗体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230167199A1 (ja) |
EP (1) | EP4130021A4 (ja) |
JP (1) | JPWO2021193553A1 (ja) |
KR (1) | KR20230005165A (ja) |
CN (1) | CN115397833A (ja) |
AU (1) | AU2021242058A1 (ja) |
BR (1) | BR112022018985A2 (ja) |
CA (1) | CA3171544A1 (ja) |
TW (1) | TW202202514A (ja) |
WO (1) | WO2021193553A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016010161A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | 多量体IgA型遺伝子組換え抗体及びその利用 |
JP2017512208A (ja) * | 2014-02-10 | 2017-05-18 | アイジーエム バイオサイエンス, インコーポレイテッド | IgA多重特異性結合分子 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016010160A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | 抗インフルエンザウイルス抗体及びその利用 |
-
2021
- 2021-03-19 TW TW110110021A patent/TW202202514A/zh unknown
- 2021-03-22 BR BR112022018985A patent/BR112022018985A2/pt unknown
- 2021-03-22 CN CN202180023085.3A patent/CN115397833A/zh active Pending
- 2021-03-22 CA CA3171544A patent/CA3171544A1/en active Pending
- 2021-03-22 US US17/906,956 patent/US20230167199A1/en active Pending
- 2021-03-22 WO PCT/JP2021/011753 patent/WO2021193553A1/ja unknown
- 2021-03-22 EP EP21774659.3A patent/EP4130021A4/en active Pending
- 2021-03-22 KR KR1020227036654A patent/KR20230005165A/ko unknown
- 2021-03-22 AU AU2021242058A patent/AU2021242058A1/en active Pending
- 2021-03-22 JP JP2022510493A patent/JPWO2021193553A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017512208A (ja) * | 2014-02-10 | 2017-05-18 | アイジーエム バイオサイエンス, インコーポレイテッド | IgA多重特異性結合分子 |
WO2016010161A1 (ja) * | 2014-07-18 | 2016-01-21 | 国立感染症研究所長が代表する日本国 | 多量体IgA型遺伝子組換え抗体及びその利用 |
JP6564777B2 (ja) | 2014-07-18 | 2019-08-21 | 国立感染症研究所長 | 多量体IgA型遺伝子組換え抗体を含む組成物及びその利用 |
Non-Patent Citations (3)
Title |
---|
HIKI, YOSHIYUKI: "Kidney Disease: Progress of Diagnosis and Treatment, II. Putting Laboratory Data to Use, 3. Abnormality in IgA", NIHON NAIKA GAKKAI ZASSHI, vol. 97, no. 5, 30 November 2007 (2007-11-30), JP , pages 962 - 970, XP009540151, ISSN: 0021-5384, DOI: 10.2169/naika.97.962 * |
See also references of EP4130021A4 |
T. TILLER ET AL., J IMMUNOL METHODS, vol. 329, 2008, pages 112 - 24 |
Also Published As
Publication number | Publication date |
---|---|
EP4130021A1 (en) | 2023-02-08 |
CA3171544A1 (en) | 2021-09-30 |
TW202202514A (zh) | 2022-01-16 |
BR112022018985A2 (pt) | 2022-11-01 |
JPWO2021193553A1 (ja) | 2021-09-30 |
US20230167199A1 (en) | 2023-06-01 |
CN115397833A (zh) | 2022-11-25 |
AU2021242058A1 (en) | 2022-11-17 |
EP4130021A4 (en) | 2024-05-08 |
KR20230005165A (ko) | 2023-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI830761B (zh) | 針對cldn18.2和cd3之抗體構建體 | |
JP6639464B2 (ja) | Ig様分子を生産する方法、Ig様分子の混合物、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法および培養物 | |
US10550185B2 (en) | Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments | |
JP6904902B2 (ja) | ドメイン交換抗体 | |
JP7138046B2 (ja) | 二特異性抗体基幹 | |
KR20200026995A (ko) | 향상된 이중 특이성 폴리펩티드 분자 | |
JP7344206B2 (ja) | 二重特異性抗体製品のための連続製造プロセス | |
KR20190065375A (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
WO2021193553A1 (ja) | 多量体IgA抗体の作製法及び多重特異性多量体IgA抗体 | |
JP7440516B2 (ja) | 切断多価多量体 | |
KR20220017909A (ko) | 단백질 다량체화를 위한 변이체 도메인 및 그의 분리 | |
WO2023011650A1 (zh) | 一种多特异性抗体及其用途 | |
JP2023547662A (ja) | Cldn6及びcd3に選択的に結合するポリペプチド構築物 | |
TW202321312A (zh) | 包含基於mhc或mhc樣蛋白的異源二聚體的二價雙特異性嵌合抗體 | |
CN117545768A (zh) | 二硫键结合的结合多肽的筛选和表达的方法 | |
KR20210042325A (ko) | 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21774659 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3171544 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022510493 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022018985 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021774659 Country of ref document: EP Effective date: 20221024 |
|
ENP | Entry into the national phase |
Ref document number: 112022018985 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220922 |
|
ENP | Entry into the national phase |
Ref document number: 2021242058 Country of ref document: AU Date of ref document: 20210322 Kind code of ref document: A |